Vol 31, No 2 (2024)
Letter to the Editor
Published online: 2024-04-26
Lipoprotein(a): an important consideration for DAPT therapy after PCI
Abstract
Not available
References
- Cui K, Wu S, Yin D, et al. Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations. Cardiol J. 2024; 31(1): 32–44.
- Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol. 1998; 18(9): 1393–1399.
- Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007; 13(9): 1086–1095.
- Tsironis LD, Mitsios JV, Milionis HJ, et al. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res. 2004; 63(1): 130–138.
- Barre DE. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor. Thromb Res. 2007; 119(5): 601–607.
- Zhu P, Tang XF, Song Y, et al. Association of lipoprotein(a) with platelet aggregation and thrombogenicity in patients undergoing percutaneous coronary intervention. Platelets. 2021; 32(5): 684–689.
- Kubica J, Adamski P, Gorog D, et al. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiology Journal. 2022; 29(1): 148–153.